These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 25376500)
1. Immunization of mice with Plasmodium TCTP delays establishment of Plasmodium infection. Taylor KJ; Van TT; MacDonald SM; Meshnick SR; Fernley RT; Macreadie IG; Smooker PM Parasite Immunol; 2015 Jan; 37(1):23-31. PubMed ID: 25376500 [TBL] [Abstract][Full Text] [Related]
2. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain. Goschnick MW; Black CG; Kedzierski L; Holder AA; Coppel RL Infect Immun; 2004 Oct; 72(10):5840-9. PubMed ID: 15385485 [TBL] [Abstract][Full Text] [Related]
3. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge. Rotman HL; Daly TM; Long CA Exp Parasitol; 1999 Jan; 91(1):78-85. PubMed ID: 9920045 [TBL] [Abstract][Full Text] [Related]
4. Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses. Lynch MM; Cernetich-Ott A; Weidanz WP; Burns JM Clin Vaccine Immunol; 2009 Mar; 16(3):293-302. PubMed ID: 19116303 [TBL] [Abstract][Full Text] [Related]
5. Plasmodium chabaudi: immunogenicity of a highly antigenic glutamate-rich protein. Wiser MF; Giraldo LE; Schmitt-Wrede HP; Wunderlich F Exp Parasitol; 1997 Jan; 85(1):43-54. PubMed ID: 9024201 [TBL] [Abstract][Full Text] [Related]
6. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge. Kedzierski L; Black CG; Coppel RL Infect Immun; 2000 Oct; 68(10):6034-7. PubMed ID: 10992516 [TBL] [Abstract][Full Text] [Related]
7. CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. Xu H; Hodder AN; Yan H; Crewther PE; Anders RF; Good MF J Immunol; 2000 Jul; 165(1):389-96. PubMed ID: 10861076 [TBL] [Abstract][Full Text] [Related]
8. A highly infectious Plasmodium yoelii parasite, bearing Plasmodium falciparum circumsporozoite protein. Zhang M; Kaneko I; Tsao T; Mitchell R; Nardin EH; Iwanaga S; Yuda M; Tsuji M Malar J; 2016 Apr; 15():201. PubMed ID: 27068454 [TBL] [Abstract][Full Text] [Related]
9. Rhop-3 protein conservation among Plasmodium species and induced protection against lethal P. yoelii and P. berghei challenge. Wang T; Fujioka H; Drazba JA; Sam-Yellowe TY Parasitol Res; 2006 Aug; 99(3):238-52. PubMed ID: 16541261 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii. Kedzierski L; Black CG; Stowers AW; Goschnick MW; Kaslow DC; Coppel RL Vaccine; 2001 Sep; 19(32):4661-8. PubMed ID: 11535314 [TBL] [Abstract][Full Text] [Related]
12. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection. Petritus PM; Burns JM J Immunol; 2008 Jan; 180(1):444-53. PubMed ID: 18097046 [TBL] [Abstract][Full Text] [Related]
13. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Narum DL; Ogun SA; Thomas AW; Holder AA Infect Immun; 2000 May; 68(5):2899-906. PubMed ID: 10768987 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and protective efficacy of a Plasmodium yoelii Hsp60 DNA vaccine in BALB/c mice. Sanchez GI; Sedegah M; Rogers WO; Jones TR; Sacci J; Witney A; Carucci DJ; Kumar N; Hoffman SL Infect Immun; 2001 Jun; 69(6):3897-905. PubMed ID: 11349057 [TBL] [Abstract][Full Text] [Related]
15. Mice immunised with synthetic peptide from N-terminal conserved region of merozoite surface antigen-2 of human malaria parasite Plasmodium falciparum can control infection induced by Plasmodium yoelii yoelii 265BY strain. Lougovskoi AA; Okoyeh NJ; Chauhan VS Vaccine; 1999 Dec; 18(9-10):920-30. PubMed ID: 10580206 [TBL] [Abstract][Full Text] [Related]
16. Protective efficacy against malaria of a combination sporozoite and erythrocytic stage vaccine. Wang R; Charoenvit Y; Daly TM; Long CA; Corradin G; Hoffman SL Immunol Lett; 1996 Nov; 53(2-3):83-93. PubMed ID: 9024983 [TBL] [Abstract][Full Text] [Related]
17. Prophylactic potential of liposomized integral membrane protein of Plasmodium yoelii nigeriensis against blood stage infection in BALB/c mice. Sharma SK; Gupta C; Dwivedi V; Misra-Bhattacharya S; Mohammad O Vaccine; 2007 Mar; 25(11):2103-11. PubMed ID: 17241709 [TBL] [Abstract][Full Text] [Related]
18. Immunity to erythrocytic stages of malarial parasites. Long CA; Daly TM; Kima P; Srivastava I Am J Trop Med Hyg; 1994; 50(4 Suppl):27-32. PubMed ID: 7909653 [TBL] [Abstract][Full Text] [Related]
19. Antibodies against ribosomal phosphoprotein P0 of Plasmodium falciparum protect mice against challenge with Plasmodium yoelii. Chatterjee S; Singh S; Sohoni R; Singh NJ; Vaidya A; Long C; Sharma S Infect Immun; 2000 Jul; 68(7):4312-8. PubMed ID: 10858250 [TBL] [Abstract][Full Text] [Related]
20. Expression of non-TLR pattern recognition receptors in the spleen of BALB/c mice infected with Plasmodium yoelii and Plasmodium chabaudi chabaudi AS. Rosanas-Urgell A; Martin-Jaular L; Ricarte-Filho J; Ferrer M; Kalko S; Kimura E; Del Portillo HA Mem Inst Oswaldo Cruz; 2012 May; 107(3):410-5. PubMed ID: 22510838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]